Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the ...

Fintel reports that on March 5, 2025, Jefferies initiated coverage of Krystal Biotech (NasdaqGS:KRYS) with a Buy ...

Therefore, the Zacks rating upgrade for Krystal Biotech basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Chardan raised the firm’s price target on Krystal Biotech (KRYS) to $218 from $212 and keeps a Buy rating on the shares after the company reported Q4 results and provided an update on the ...

NASDAQ:KRYS opened at $187.86 on Thursday. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The firm has a market capitalization of $5.41 billion, a price-to-earnings ...

Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial ...

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy? Shares of Exelixis, Inc. (NASDAQ: EXEL) have risen 20.7% in the past three months compared with the industry's growth of 6.3% ...

Krystal Motor Homes left the recreational vehicle market after the 2010 model year. MOTORHOMES - No information after 2010. In addition to what is standard, prices include 3rd battery, 6-way drivers ...

Krystal Integrated Services Ltd share price was down by -4.62% from the previous closing price of ₹697.70. Who are peers of Krystal Integrated Services Ltd? The peers of Krystal Integrated ...

Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Jefferies ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...